

A<sup>3</sup> 36. (Amended) The composition of claim 32 [or 35], further comprising a colloidal dispersion system, wherein the UCP inhibitor and the plasma membrane targeting molecule are incorporated into the colloidal dispersion system.

A<sup>4</sup> 63. (Amended) The method of claim 61 [or 62], wherein the lysosomal UCP activity is modified by contacting the cell with a lysosomal UCP inhibitor.

**REMARKS**

Prior to calculating the claims fees, we request that the claims be amended as described above. The amendments change all multiple dependent claims to single dependent claims. Thus, no multiple dependent claims are pending in the case. No. new matter has been added.

Respectfully submitted,



Helen C. Lockhart, Reg. No. 39,248  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, MA 02210-2211  
Tel. (617) 720-3500

Docket No. I0277/7009(HCL)  
Date: December 22, 2000  
**X12/24/00**